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Abstract
Retrovirology announces an annual prize to recognize one outstanding mid-career retrovirologist.
The silent majority
In his US presidential campaigns, Richard Nixon
famously popularized the concept of a "silent majority".
Fundamentally what Nixon meant was that the stalwart
contributors in any given population tend to be a faceless
and non-vocal "majority". Applying Nixon's term to sci-
ence, where is our "silent majority"?
I recently returned from a large international meeting
where numerous awards were presented to wunderkinds
(i.e. Young Investigator Awards) and senior statesmen/
stateswomen of science (i.e. Lifetime Achievement
Awards). Curiously, I found subjectively that the majority
of the best work was being presented by a glum-looking
bunch of scientists traversing "midlife crises" (i.e. individ-
uals who uncannily resemble me!). It struck me that argu-
ably the most productive denizens of science are those in
the 45 to 60 age group (who are no longer young investi-
gators and not yet competitive for lifetime achievements);
and they are our equivalent of Nixon's "silent majority".
The Retrovirology Prize
To my knowledge, there is no significant scientific prize
that is age-restricted to mid-career scientists (i.e. between
the ages of 45 to 60). Although mid-life scientists do and
have competed ably for numerous non-age restricted
awards, a unique niche is fulfilled by a prize that specifi-
cally recognizes this increasingly large and productive age
group. Moreover, I am not aware of a prize limited to ret-
rovirologists. Beginning this year, Retrovirology will recog-
nize annually through the Retrovirology Prize one 45- to
60- year-old retrovirologist.
The selection process
This editorial kicks-off the 2005 call for nominations for
the Retrovirology Prize. We envisage an approximate alter-
nation of the Prize yearly between a non-HIV retrovirolo-
gist (2005 and odd years) and an HIV retrovirologist
(2006 and even years). There can be some discretion on
this criterion exercised from time-to-time by the selection
committee. A nomination includes a statement (1000
words or less) of significant contributions to retrovirology
research and a curriculum vitae of the nominee. The selec-
tion committee is composed of the Editors (currently, M.
Benkirane, B. Berkhout, M. Fujii, K.T. Jeang, M. Lairmore,
A. Lever, and M. Wainberg) of Retrovirology. All nomina-
tions to the selection committee must come through an
Editorial Board member of Retrovirology. Candidates may
self-nominate, but they must ask a Retrovirology Editorial
board member to communicate their nominations to the
selection committee. A list of Editorial Board members
can be found at the Retrovirology website www.retrovirol-
ogy.com. All Retrovirology Editors and Editorial Board
members are eligible for nomination with the exception
of the Editor-in-Chief who will administer the final selec-
tion decision. For 2005, all nominations must be received
by June 1. The Retrovirology Prize consists of an attractive
trophy, a cash award, and a biographical article published
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in Retrovirology about the winner and his or her scientific
contributions to retrovirology.
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